Bridgepoint Group (LON:BPT) Upgraded by Citigroup to “Buy” Rating

Bridgepoint Group (LON:BPT) was upgraded by Citigroup to a “buy” rating in a report issued on Thursday,London Stock Exchange reports. The brokerage presently has a GBX 410 ($5.33) price objective on the stock. Citigroup’s price objective would indicate a potential upside of 22.02% from the stock’s previous close.

Bridgepoint Group Trading Up 1.7 %

Shares of BPT traded up GBX 5.60 ($0.07) during mid-day trading on Thursday, reaching GBX 336 ($4.37). The stock had a trading volume of 291,683 shares, compared to its average volume of 3,969,312. Bridgepoint Group has a 52-week low of GBX 202.40 ($2.63) and a 52-week high of GBX 410 ($5.33). The firm has a market cap of £2.78 billion, a price-to-earnings ratio of 61.04, a P/E/G ratio of 0.61 and a beta of 1.72. The business’s fifty day moving average is GBX 359.12 and its 200 day moving average is GBX 346.42. The company has a debt-to-equity ratio of 12.89, a current ratio of 4.98 and a quick ratio of 3.60.

Bridgepoint Group (LON:BPT) last announced its quarterly earnings results on Thursday, March 13th. The company reported GBX 19.50 ($0.25) earnings per share (EPS) for the quarter. Bridgepoint Group had a net margin of 16.74% and a return on equity of 6.10%. On average, sell-side analysts predict that Bridgepoint Group will post 17.4062165 EPS for the current fiscal year.

Bridgepoint Group Company Profile

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.